Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
11/11/26
Acarix AB (publ) (ACIXF)
Wednesday
8:40 PM
ThesisAcarix AB (publ): the setup is constructive — Clinical trial data releases and peer-reviewed publication outcomes demonstrating CADScor diagnostic accuracy versus…
Speculative growth investors and biotech/medtech specialists willing to accept binary outcomes and extreme volatility in exchange…
High sensitivity through multiple channels: (1) As a cash-burning growth company…
Watch on earnings: Monthly cash burn rate and quarterly cash balance updates relative to stated runway guidance, CADScor device unit sales and installed base growth in Scandinavian and broader European markets, Clinical trial enrollment rates and data readout timelines for pivotal studies supporting regulatory submissions.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $14M to $33M as clinical trial data releases and peer-reviewed publication outcomes demonstrating cadscor diagnostic accuracy versus.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
